Palo Alto Newswire

Comprehensive Real-Time News Feed for Palo Alto, CA.

Results 1 - 8 of 8 for "u:seekingalpha.com" in Palo Alto, CA

  1. Tesla Has Outed The Good News Early, Now What?Read the original story w/Photo

    Apr 8, 2015 | Seeking Alpha

    In two of my past articles, " Why Is Tesla Throttling Production? " and " Ripping The Shorts' Faces Off! ", I explained why I thought Tesla's Q1 2015 deliveries guidance was too low. Indeed, I even called it "comically low".

    Comment?

  2. Be Careful Before You Jump Into Yet Another Rally In SysorexRead the original story w/Photo

    Apr 8, 2015 | Seeking Alpha

    Sysorex shares were up 100% at their intra-day highs earlier today after the company announced the award of a five-year $20 billion NASA contract. Its shares have been volatile rising from $1 to $18 and back to $1 in just the last two years, and within that it has had several 50%-100%+ rallies that.

    Comment?

  3. Invitae Genomic Testing Heading Into IPORead the original story w/Photo

    Feb 11, 2015 | Seeking Alpha

    San-Fran-based genomic testing company NVTA is set to IPO on NYSE Thurs., 2.12.2015; lead underwriter is JP Morgan. Invitae Corp. is a genomic testing company that offers consolidated testing services for a range of genetically contracted diseases.

    Comment?

  4. IPO Preview: Carbylan TherapeuticsRead the original story w/Photo

    Feb 6, 2015 | Seeking Alpha

    Initial focus is on the development of Hydros-TA, its proprietary, potentially best-in-class intra-articular, or IA, injectable product candidate to treat pain associated with osteoarthritis. Based in Palo Alto, CA, Carbylan Therapeutics scheduled a $75 million IPO on Nasdaq with a market capitalization of $198 million at a price range midpoint of $13 for Wednesday, Feb. 4, 2015.

    Comment?

  5. With A Well Developed Pipeline, Ascendis Pharma Looks Promising At IPORead the original story w/Photo

    Jan 28, 2015 | Seeking Alpha

    ASND, a clinical stage biopharmaceutical firm that develops treatments for unmet medical needs, plans to raise ~$100 million in its upcoming IPO, set for 1.29.2015. While we are concerned about ASND's growing losses-these are typical of a clinical stag biotech firm and should not be taken as sole indication of future success or failure.

    Comment?

  6. With A Well Developed Pipeline, Ascendis Pharma Looks Promising At IPORead the original story w/Photo

    Jan 28, 2015 | Seeking Alpha

    ASND, a clinical stage biopharmaceutical firm that develops treatments for unmet medical needs, plans to raise ~$100 million in its upcoming IPO, set for 1.29.2015. While we are concerned about ASND's growing losses-these are typical of a clinical stag biotech firm and should not be taken as sole indication of future success or failure.

    Comment?

  7. IPO Preview: HortonworksRead the original story w/Photo

    Dec 12, 2014 | Seeking Alpha

    Based in Palo Alto, CA, Hortonworks scheduled a $78 million IPO on Nasdaq with a market capitalization of $538 million at a price range midpoint of $13 for Friday, Dec. 12, 2014. HDP seeks to advance the market adoption of Hadoop and provide enterprises with a new data management solution that enables them to harness the power of big data to transform their businesses through more effective and efficient management of their valuable data assets.

    Comment?

  8. REIT Focus: Essex Properties, Inc.Read the original story w/Photo

    Nov 18, 2014 | Seeking Alpha

    ESS is an apartment REIT that acquires, owns, develops, manages and operates 239 Class A apartment properties with 56,622 units located in Northern CA, Southern CA, Seattle and Phoenix. ESS is an excellently managed REIT with a Class A portfolio of apartment assets, however, we are recommending sale of the stock because of a very high valuation.

    Comment?

Palo Alto Job Listings
View or post Palo Alto job listings on Topix.
Palo Alto Real Estate
News, listings, and foreclosures in Palo Alto from Topix.
Palo Alto Mortgages
Find mortgage rates in Palo Alto on Topix.